- Home
- ATCH vs SONN Comparison
ATCH vs SONN Comparison
Compare ATCH & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATCH
- SONN
- Stock Information
- Founded
- ATCH 2022
- SONN N/A
- Country
- ATCH United States
- SONN United States
- Employees
- ATCH N/A
- SONN N/A
- Industry
- ATCH
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- ATCH
- SONN Health Care
- Exchange
- ATCH Nasdaq
- SONN Nasdaq
- Market Cap
- ATCH 3.2M
- SONN 3.8M
- IPO Year
- ATCH N/A
- SONN N/A
- Fundamental
- Price
- ATCH $0.20
- SONN $9.77
- Analyst Decision
- ATCH
- SONN Strong Buy
- Analyst Count
- ATCH 0
- SONN 1
- Target Price
- ATCH N/A
- SONN $20.00
- AVG Volume (30 Days)
- ATCH 1.6M
- SONN 11.0M
- Earning Date
- ATCH 08-27-2025
- SONN 08-13-2025
- Dividend Yield
- ATCH N/A
- SONN N/A
- EPS Growth
- ATCH N/A
- SONN N/A
- EPS
- ATCH 2.67
- SONN N/A
- Revenue
- ATCH N/A
- SONN $1,000,000.00
- Revenue This Year
- ATCH N/A
- SONN $5,376.22
- Revenue Next Year
- ATCH N/A
- SONN N/A
- P/E Ratio
- ATCH $0.08
- SONN N/A
- Revenue Growth
- ATCH N/A
- SONN 978.39
- 52 Week Low
- ATCH $0.18
- SONN $1.08
- 52 Week High
- ATCH $45.60
- SONN $19.30
- Technical
- Relative Strength Index (RSI)
- ATCH 40.63
- SONN 93.10
- Support Level
- ATCH $0.20
- SONN $4.19
- Resistance Level
- ATCH $0.22
- SONN $19.30
- Average True Range (ATR)
- ATCH 0.01
- SONN 1.74
- MACD
- ATCH 0.01
- SONN 0.76
- Stochastic Oscillator
- ATCH 47.03
- SONN 47.64
About ATCH AtlasClear Holdings Inc. Common Stock
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and innovative financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.